We are delighted that the Medicines and Healthcare Products Regulatory Agency (MHRA) has agreed to begin the process to change legislation to allow schools to hold a spare adrenaline auto-injector (AAI).
“Supply of adrenaline auto-injectors to schools for emergency use in the event of one of the pupils having an anaphylactic reaction
The Commission considered and discussed a paper on the use of Adrenaline Autoinjectors in schools. Adrenaline Auto-Injectors (AAI) are self-injecting devices developed as a first-aid measure for the treatment of anaphylaxis. They can be administered by patients or parents, carers and teachers who are not healthcare professionals. Following an extensive discussion: The Commission recommended a change to the legislation to allow schools to hold one or more adrenaline auto-injector devices in order to administer adrenaline to a child known to have a severe allergy and who has been prescribed an AAI, in the event of that child suffering an anaphylactic attack. The Commission recommended that appropriate guidance and protocols must be developed to support this change in legislation. The Commission recommended that the details of the guidance and protocols should be developed by the Department of Health in conjunction with local providers/commissioning groups. The Commission also commented that MAHs of AAIs should be encouraged to standardise the colour coding for the needle end of devices to minimise the risk of needle-stick injury to the person administering the AAI.”
Anaphylaxis Campaign’s Mandy East will be speaking about the “Spare AAI in Schools” campaign at our conference for healthcare professionals on 10th November. If you are a healthcare professional with an interest in allergy, find out more and book now here.
We will keep you updated as this campaign progresses.